Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.2477
+$0.0097 · +4.08%
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Regular session
$0.2477
+$0.0097 · +4.08%
Regular session · ET · Market data may be delayed.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Day range
Current $0.2477
52-week range
Current $0.2477
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
46
Mixed
Risk
72
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Day range
Current $0.2477
52-week range
Current $0.2477
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.33M USD | 2.82M USD | 21.05M USD | 13.54M USD | 10.14M USD |
| Cost of goods sold | 2.87M USD | — | — | — | — |
| Gross profit | 7.46M USD | 2.82M USD | 21.05M USD | 13.54M USD | 10.14M USD |
| Research and development | 114.15M USD | 107.35M USD | 88.15M USD | 59.82M USD | 44.95M USD |
| Selling, general, and administrative | 31.99M USD | 29.56M USD | 25.49M USD | 20.35M USD | 13.83M USD |
| Operating expenses | 143.27M USD | 137.64M USD | 114.51M USD | 80.17M USD | 58.78M USD |
| Interest income | 8.82M USD | 12.07M USD | 8M USD | 1.59M USD | 16K USD |
| Interest expense | 2.77M USD | 3.65M USD | 3.76M USD | 1.18M USD | — |
| Depreciation and amortization | 2.87M USD | 4.11M USD | 5.36M USD | 5.14M USD | 3.33M USD |
| Operating income | −135.81M USD | −134.82M USD | −93.46M USD | −66.64M USD | −48.64M USD |
| Net income | −129.77M USD | −127.5M USD | −89.22M USD | −66.22M USD | −48.63M USD |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.34M0.00%2.3T USD0.03%$381.68-0.07%
Vanguard Extended Market ETFVXF485.8K0.00%95.4B USD0.05%$234.27-0.31%
iShares Micro-Cap ETFIWC37.77K0.00%1.32B USD0.60%$182.3-0.39%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM20K0.01%116.88M USD0.73%$15.86-0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
